Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis - PubMed
3 hours ago
- #Meta-Analysis
- #Neuropsychiatry
- #GLP-1 RA
- GLP-1 RAs may reduce the risk of idiopathic Parkinson's disease (HR 0.70, 95% CI: 0.53-0.92).
- No significant improvements in motor symptoms for established Parkinson's disease were observed.
- Reduced risk of cannabis use disorder (HR 0.55, 95% CI: 0.39-0.77) but no effect on opioid use disorder.
- Liraglutide reduced binge frequency in binge eating disorder compared to placebo.
- Lower reported risk of suicidality in observational studies (OR 0.34, 95% CI: 0.18-0.63), but not with Semaglutide alone.
- No associations observed for depression or anxiety.
- Mixed findings for dementia: reduced risk of Alzheimer's disease compared to non-exposed controls (RR 0.37, 95% CI: 0.14-0.96), but no benefit versus SGLT2 inhibitors.
- Evidence certainty ranged from moderate to very low, indicating significant heterogeneity and imprecision.